Loading
Surgeon who led MSLT-II, showing that removing all lymph nodes after a positive sentinel node does not improve melanoma survival.
Mark Faries was principal investigator of MSLT-II, the randomised trial showing completion lymph node dissection after a positive sentinel node biopsy does not improve melanoma-specific survival, which ended routine completion dissection worldwide, and a senior investigator of MSLT-I with Donald Morton. He leads surgical aspects of neoadjuvant immunotherapy trials and the melanoma programme at the Angeles Clinic.
Shares Cedars-Sinai Cancer, Sentinel lymph node biopsy and the tags surgery, de-escalation.
Shares Sentinel lymph node biopsy and the tags surgery, de-escalation.
Shares Melanoma and the tags melanoma, surgery.
Shares Melanoma and the tags melanoma, surgery.
Shares Sentinel lymph node biopsy, Melanoma.
Shares the tags surgery, de-escalation.
Shares the tags surgery, de-escalation.
Shares the tags surgery, de-escalation.